About SciRhom
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
Press releases
Blog
Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing
In July, HTGF portfolio company SciRhom announced one of the largest financing rounds in German biotechnology this year and will soon begin clinical trials of its first drug. The company’s unique therapeutic approach targets a central node of the immune system. In this interview, company co-founder and current SciRhom Managing Director and COO Jens Ruhe, his Co-Managing Director and CEO Jan Poth and Frank Hensel, Principal at HTGF, provide insights into the collaboration that has been in p
Press
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy.
Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa
Info & Contact
Address
Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland
82152 Planegg/Martinsried
Deutschland
In portfolio
27. Oct 2016
Sector
Dr. Frank Hensel
Principal / Authorized signatory